Skip to content

7th Annual Blueprint for Breakthrough Forum

7th Annual Blueprint for Breakthrough Forum

7th Annual Blueprint for Breakthrough Forum
Research and Reimbursement in the Age of Precision Medicine
September 13, 2018
The Four Seasons
2800 Pennsylvania Ave NW, Washington, DC 20007
8:30AM – 1:00PM EDT

Thank you to all that attended our event! To access the meeting white paper, please Click HERE, and check our Engaging Innovation blog for a post-event recap. Check below for links to presentations.

Friends of Cancer Research (Friends) and Alexandria Real Estate Equities, Inc. (Alexandria) are proud to announce the seventh annual Blueprint for Breakthrough forum. Friends and Alexandria will convene stakeholders across academia, government, industry, research and advocacy organizations, and other interested stakeholders with the intent of developing consensus on critical aspects for the future development of diagnostic tests. With expert input from a multistakeholder group, a whitepaper containing considerations for the development, use, and reimbursement of NGS-based diagnostic tests will be distributed and discussed at the meeting. Scroll through below to view the final agenda.

Registration has closed. If you have any questions, please contact Heather Chaney at (202) 944-6719 or

Final Agenda

8:30 AM – Registration and Breakfast

9:00 AM – Opening Remarks

  • Ellen Sigal, Friends of Cancer Research
  • Lynne Zydowsky, Alexandria Real Estate Equities, Inc.

9:05 AM – Keynote Address

  • Scott Gottlieb, U.S. FDA

9:30 AM – Panel 1: Evidence to support clinical implementation and reimbursement
Moderator: Kavita Patel, Brookings Institution

Overview of CMS’ National Coverage Decision—Katherine Szarama, CMS
Mechanisms for Collecting Evidence Overtime—Jon Hirsch, Syapse

Alex Lazar, MD Anderson Cancer Center
Girish Putcha, Palmetto GBA
John Simmons, Personal Genome Diagnostics

Jon Hirsch, Syapse
Katherine Szarama, CMS
Reena Philip, U.S. FDA

Seth Sadis, Thermo Fisher Scientific

11:00 AM – Break

11:15 AM – Panel 2: Policy priorities for supporting development of high-quality diagnostic tests
Moderator: Kate Rawson, Prevision Policy

Eric Rubin, Merck

Florence Kurttila, Patient advocate
Jennifer Malin, UnitedHealth Group
Joe Chin, CMS
Mike Berger, Memorial Sloan Kettering Cancer Center
Timothy Stenzel, U.S. FDA
Troy Cox, Foundation Medicine

12:30 – Closing Remarks
Jeff Allen, Friends of Cancer Research